Form D · Biotechnology
Artio Medical, Inc.
Prairie Village, KS · CIK 0001595722
Offering snapshot reported Dec 21, 2022 · SEC filing
- Reported sold
- $5.07M Offering amount: $10M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Dec 8, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 21, 2022 | Initial | $5,068,881 | No comparison | 13 | SEC filing |
| Jul 18, 2022 | Amendment | $16,280,692 | $11,482,816vs Apr 4, 2022 | 90 | SEC filing |
| Apr 4, 2022 | Amendment | $4,797,876 | No comparison | 26 | SEC filing |
| Feb 17, 2022 | Amendment | $11,384,094 | $5,978,736vs Sep 7, 2021 | 58 | SEC filing |
| Feb 17, 2022 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Sep 7, 2021 | Amendment | $5,405,358 | No comparison | Not reported | SEC filing |
| Aug 2, 2021 | Amendment | $7,000,000 | No comparison | 56 | SEC filing |
| Jul 30, 2021 | Initial | Yet to sell | No comparison | Not reported | SEC filing |
| Feb 18, 2021 | Amendment | $4,977,230 | No comparison | 68 | SEC filing |
| Feb 18, 2021 | Amendment | $4,977,230 | $0vs Feb 18, 2021 | 68 | SEC filing |
| Feb 4, 2021 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Oct 27, 2020 | Amendment | $402,246 | No comparison | 8 | SEC filing |
| Oct 27, 2020 | Amendment | Yet to sell | No comparison | 0 | SEC filing |
| Oct 27, 2020 | Amendment | $17,488,800 | No comparison | 132 | SEC filing |
| Jul 31, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| May 29, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| May 28, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Mar 17, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 3, 2014 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-468260
convertible into equity
Source: Form D, filed Dec 21, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Ayres | Executive |
| F. Nicholas Franano | Executive |
| Frank Nicholas Franano | Director, Executive |
| Nathaniel Hagedorn | Director |
| Jenny Martin | Executive |
| Joseph Mc Connell | Executive |
| Sean Morris | Director, Executive |
| Maria Sainz | Director |
| James M. Schultz | Director |
| Abhinav Shukla | Director |
| Jeff Weinrich | Director |
| William P Whitaker | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7400 State Line Road, Suite 202
Prairie Village, KS, 66208
Prairie Village, KS, 66208